Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03320070 · ClinicalTrials.gov registry record · Phase 4
Acthar Gel in Participants With Pulmonary Sarcoidosis
A Phase 4 study, sponsored by Mallinckrodt.
- Completed
- Registry status
- Phase 4
- Development phase
- 55
- Enrollment target
NCT03320070 is a Phase 4 study that has completed, run by Mallinckrodt. The registered enrollment target is 55 participants.
The verdict
NCT03320070, a Phase 4 study, has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if Acthar Gel is safe and effective to treat pulmonary sarcoidosis. Participants will be randomly assigned (like flipping a coin) to receive a shot under their skin of Acthar Gel or a matching placebo gel that has no drug in it. They will receive their assigned shot twice a week for 24 weeks. All participants who complete the 24-week treatment period will be eligible to receive Acthar Gel for 24 more weeks, even if they were originally in the placebo group.
Interventions
- DRUG Placebo
- DRUG Acthar Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2018-02-21 |
| Est. Completion | 2021-11-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03320070
The ClinicalTrials.gov registry entry for NCT03320070 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03320070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03320070 about?
NCT03320070 is a clinical study titled "Acthar Gel in Participants With Pulmonary Sarcoidosis". The purpose of this study is to find out if Acthar Gel is safe and effective to treat pulmonary sarcoidosis. Participants will be randomly assigned (like flipping a coin) to receive a shot under their skin of Acthar Gel or a matching placebo gel that has no drug in it. They will receive their assig...
What is the current status of trial NCT03320070?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 55 participants. The study started on 2018-02-21. Estimated completion is 2021-11-15.
What interventions are being tested in trial NCT03320070?
The interventions under investigation include: Placebo (DRUG), Acthar Gel (DRUG).
Who is sponsoring clinical trial NCT03320070?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.